Medtronic has reported revenue gains across several of its medical device franchises, leading the company to ... aortic valve ...

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...

For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

5.0%). The OPTION trial included 1,600 patients. In the trial, approximately 60% of device patients had their WATCHMAN FLX ...

Ablation, a procedure to treat abnormal electrical short circuits caused by a heart attack and is usually reserved for patients who do not improve with medication, may be a better first-line treatment ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...